Biovail/Depomed’s Glumetza Clears FDA For Type 2 Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies are highlighting potential dosing and tolerability advantages for Glumetza (metformin extended-release) to differentiate the drug in a crowded metformin market. Biovail is in discussions with several potential marketing partners for a U.S. launch of the antidiabetic.